Compare Illinois Tool Works Inc. (ITW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Organon & Co. Common Stock — how do they compare? Illinois Tool Works Inc. trades at $269.47 (market cap $75.85B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Illinois Tool Works Inc. is far larger — about 21× Organon & Co. Common Stock's market cap, and Illinois Tool Works Inc. pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and Organon & Co. Common Stock for 0 Days on average.
| ITW | OGN | |
|---|---|---|
Market Cap | $75.85B | $3.62B |
Volume | 960,368 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $299.60 | $13.81 |
52-Week Low | $241.07 | $5.70 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $84.70B | $11.04B |
Dividend Yield | 2.58% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $269.47, up 1.64% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of growth. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but faces headwinds from elevated P/E of 24.12 and bearish technical momentum. The company's disciplined capital allocation and sector diversification provide stability, though automotive and foodservice weaknesses present near-term challenges. Valuation appears full given current growth rates.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
